Moderna and Pfizer have both submitted applications to the FDA to authorize their bivalent candidates for emergency use, which are part original formula and part omicron. If authorized by the FDA and CDC, the new boosters are planned to be ready after Labor Day weekend.
But with the already slow uptake of boosters and second boosters, the race for new formulas geared toward omicron subvariants BA.4 and BA.5 could end in a crash, according Dr. Wu.
“Emergency pandemic funds have been drying up, imperiling already dwindling supplies of vaccines, [and] with each passing week, more Americans are greeting the coronavirus with little more than a shrug,” Dr. Wu wrote.
The other issue is fumbled communication about the necessity of the boosters, as some said the primary series offered in late 2020 and early 2021 was a one-and-done deal.
“If this fall is meant to set a precedent for subsequent vaccination campaigns, it may unspool one of the worst scenarios of all: asking shots to do so much for us that they hardly accomplish anything at all,” Dr. Wu wrote.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
